UTMD · Utah Medical Products Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $38.52M | $40.90M | $50.22M | $52.28M | $49.05M | $42.18M |
| Cost of Revenue | $16.52M | $16.76M | $20.19M | $20.09M | $18.14M | $16.63M |
| Gross Profit | $22.00M | $24.14M | $30.04M | $32.20M | $30.92M | $25.55M |
| R&D | $668.0K | $813.0K | $560.0K | $493.0K | $526.0K | $486.0K |
| SG&A | $7.88M | $7.83M | $11.02M | $10.41M | $10.10M | $9.80M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $826.0K | $730.0K | $623.0K | $612.0K | $636.0K | $655.0K |
| Operating Income | $11.40M | $13.59M | $16.78M | $19.79M | $18.88M | $13.71M |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $2.82M | $2.93M | $3.45M | $4.19M | $4.27M | $3.04M |
| Net Income | $11.29M | $13.87M | $16.64M | $16.47M | $14.79M | $10.80M |
| EPS - Basic | $3.48 | $3.96 | $4.58 | $4.53 | $4.05 | $2.95 |
| EPS - Diluted | $3.48 | $3.96 | $4.57 | $4.52 | $4.04 | $2.94 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $85.76M | $82.98M | $92.87M | $75.05M | $60.97M | $51.59M |
| Accounts Receivable | $3.52M | $4.09M | $3.39M | $5.54M | $5.13M | $4.10M |
| Inventory | $7.93M | $8.81M | $9.58M | $8.81M | $6.60M | $6.22M |
| Accounts Payable | $911.0K | $696.0K | $769.0K | $1.22M | $761.0K | $788.0K |
| Current Assets | $97.74M | $96.33M | $106.27M | $89.92M | $73.16M | $62.26M |
| Total Assets | $122.54M | $122.54M | $135.46M | $123.87M | $115.64M | $111.75M |
| Current Liabilities | $2.60M | $3.76M | $4.71M | $5.96M | $3.75M | $3.79M |
| Long-term Debt | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $3.27M | $5.11M | $7.14M | $9.62M | $8.50M | $8.92M |
| Stockholders' Equity | $119.27M | $117.43M | $128.31M | $114.25M | $107.14M | $102.82M |
| Retained Earnings | $128.65M | $129.30M | $138.34M | $126.01M | $115.31M | $110.95M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $14.69M | $14.83M | $22.28M | $21.15M | $21.20M | $20.14M |
| Investing Cash Flow | ($371.0K) | ($208.0K) | ($639.0K) | ($818.0K) | ($552.0K) | ($860.0K) |
| Financing Cash Flow | ($12.34M) | ($23.84M) | ($4.17M) | ($5.48M) | ($10.90M) | ($10.73M) |
| CapEx | $371.0K | $230.0K | $639.0K | $809.0K | $552.0K | $860.0K |
| Free Cash Flow | $14.32M | $14.60M | $21.64M | $20.34M | $20.65M | $19.28M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 57.1% | 59.0% | 59.8% | 61.6% | 63.0% | 60.6% |
| Operating margin | 29.6% | 33.2% | 33.4% | 37.9% | 38.5% | 32.5% |
| EBITDA margin | 31.7% | 35.0% | 34.6% | 39.0% | 39.8% | 34.1% |
| Net margin | 29.3% | 33.9% | 33.1% | 31.5% | 30.1% | 25.6% |
| Free cash flow margin | 37.2% | 35.7% | 43.1% | 38.9% | 42.1% | 45.7% |
| FCF / Net income | 1.27 | 1.05 | 1.30 | 1.23 | 1.40 | 1.79 |
| R&D / Revenue | 1.7% | 2.0% | 1.1% | 0.9% | 1.1% | 1.2% |
| SG&A / Revenue | 20.5% | 19.2% | 21.9% | 19.9% | 20.6% | 23.2% |
| Effective tax rate | 20.0% | 17.4% | 17.2% | 20.3% | 22.4% | 22.0% |
| Return on assets | 9.2% | 11.3% | 12.3% | 13.3% | 12.8% | 9.7% |
| Return on equity | 9.5% | 11.8% | 13.0% | 14.4% | 13.8% | 10.5% |
| Return on invested capital | 7.6% | 9.6% | 10.8% | 13.8% | 13.7% | 10.4% |
| Liquidity | ||||||
| Current ratio | 37.62 | 25.64 | 22.56 | 15.09 | 19.53 | 16.42 |
| Quick ratio | 34.57 | 23.29 | 20.53 | 13.61 | 17.77 | 14.78 |
| Cash ratio | 33.01 | 22.09 | 19.72 | 12.59 | 16.28 | 13.61 |
| Leverage | ||||||
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt / Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt / EBITDA | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.03 | 1.04 | 1.06 | 1.08 | 1.08 | 1.09 |
| Liabilities / Assets | 0.03 | 0.04 | 0.05 | 0.08 | 0.07 | 0.08 |
| Efficiency | ||||||
| Asset turnover | 0.31 | 0.33 | 0.37 | 0.42 | 0.42 | 0.38 |
| Inventory turnover | 2.08 | 1.90 | 2.11 | 2.28 | 2.75 | 2.67 |
| Days sales outstanding | 33d | 37d | 25d | 39d | 38d | 36d |
| Days inventory outstanding | 175d | 192d | 173d | 160d | 133d | 137d |
| Days payable outstanding | 20d | 15d | 14d | 22d | 15d | 17d |
| Cash conversion cycle | 189d | 213d | 184d | 177d | 156d | 155d |
| Valuation | ||||||
| P / E | 16.1x | 15.5x | 18.4x | 22.2x | 24.8x | 28.7x |
| P / B | 1.5x | 1.8x | 2.4x | 3.2x | 3.4x | 3.0x |
| P / S | 4.7x | 5.3x | 6.1x | 7.0x | 7.5x | 7.3x |
| EV / EBITDA | 7.8x | 9.2x | 12.3x | 14.3x | 15.6x | 18.0x |
| Growth | ||||||
| Revenue growth (YoY) | -5.8% | -18.6% | -3.9% | 6.6% | 16.3% | -10.1% |
| Revenue CAGR (3y) | -9.7% | -5.9% | 6.0% | 3.7% | 7.7% | 0.6% |
| Revenue CAGR (5y) | -1.8% | -2.7% | 5.0% | 4.8% | 4.5% | 1.0% |
| Gross profit growth (YoY) | -8.9% | -19.6% | -6.7% | 4.1% | 21.0% | -13.3% |
| Operating income growth (YoY) | -16.1% | -19.0% | -15.2% | 4.8% | 37.7% | -22.3% |
| Net income growth (YoY) | -18.7% | -16.6% | 1.0% | 11.4% | 37.0% | -26.7% |
| EPS growth (YoY) | -12.1% | -13.3% | 1.1% | 11.9% | 37.4% | -25.4% |
| EPS CAGR (3y) | -8.3% | -0.7% | 15.8% | 4.7% | -6.5% | 8.8% |
| EPS CAGR (5y) | 3.4% | 0.1% | -1.6% | 14.7% | 4.6% | -1.3% |
| FCF growth (YoY) | -1.9% | -32.5% | 6.4% | -1.5% | 7.1% | 16.7% |
| FCF CAGR (5y) | -5.8% | -2.4% | 5.7% | 5.8% | 12.9% | 7.2% |
| Book value growth (YoY) | 1.6% | -8.5% | 12.3% | 6.6% | 4.2% | 1.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Product / service
$38.52M totalGynecology Electrosurgery Urology$19.72M · 51.2%
Neonatal$8.01M · 20.8%
Blood Pressure Monitoring And Accessories$6.79M · 17.6%
Obstetrics$4.00M · 10.4%
Geographic
$54.28M totalGlobal$38.52M · 71.0%
Ous$15.76M · 29.0%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
17.35
Safe
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- ✗Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✗Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing UTAH MEDICAL PRODUCTS INC against the 5 most active filers in the same SIC group.
Dividends
$1.23/share trailing 12 months · +1.7% YoY
| Ex-date | Per share |
|---|---|
| Mar 17, 2026 | $0.3100 |
| Dec 16, 2025 | $0.3100 |
| Sep 17, 2025 | $0.3050 |
| Jun 16, 2025 | $0.3050 |
| Mar 14, 2025 | $0.3050 |
| Dec 16, 2024 | $0.3050 |
| Sep 20, 2024 | $0.3000 |
| Jun 14, 2024 | $0.3000 |
| Mar 14, 2024 | $0.3000 |
| Dec 14, 2023 | $0.3000 |
| Sep 14, 2023 | $0.2950 |
| Jun 15, 2023 | $0.2950 |
| Mar 16, 2023 | $0.2950 |
| Dec 15, 2022 | $0.2950 |
| Sep 15, 2022 | $0.2900 |
| Jun 16, 2022 | $0.2900 |
| Mar 17, 2022 | $0.2900 |
| Dec 14, 2021 | $2.0000 |
| Sep 15, 2021 | $0.2850 |
| Jun 14, 2021 | $0.2850 |
| Mar 16, 2021 | $0.2850 |
| Dec 14, 2020 | $0.2850 |
| Sep 14, 2020 | $0.2800 |
| Jun 16, 2020 | $0.2800 |